pneumonia (PCP), now referred to as pneumonia (PJP), occurs in immunocompromised patients. It is particularly associated with cellular immunodeficiency due to certain diseases or treatments. The risk of PCP is likely correlated with the severity of cellular immunity damage. However, excluding AIDS, the precise degree of immunosuppression required to develop PCP is not yet clearly understood. We report the case of a 58-year-old patient who presented with progressively worsening dyspnea. The clinical examination revealed a SaO₂ of 88% on room air and the appearance of mechanic's hands. A thoracic CT scan showed interstitial lung disease (ILD). The immunological work-up was positive for antinuclear antibodies (ANA) and anti-JO-1 antibodies. Bronchoscopy with bronchoalveolar lavage (BAL) was performed, and the test for PJP came back positive.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11299875 | PMC |
| http://dx.doi.org/10.7759/cureus.63982 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Immunological characteristics of patients with anti-synthetase syndrome overlap with rheumatoid arthritis].
Beijing Da Xue Xue Bao Yi Xue Ban
December 2024
Department of Rheumatology and Immunology, Peking University People' s Hospital, Beijing 100044, China.
Article Synopsis
- - The study aimed to examine the clinical and immune system characteristics of patients with anti-synthetase syndrome (ASS) who also have rheumatoid arthritis (RA) compared to those without RA.
- - Out of 104 ASS patients with arthritis, 23.1% were diagnosed with RA and displayed notable differences such as higher rates of rapidly progressive interstitial lung disease, more tender and swollen joints, and increased bone erosion compared to the non-RA group.
- - The overlap group (ASS with RA) also had significantly altered immune cell profiles, including decreased regulatory T cells and B cells, as well as higher levels of certain inflammatory markers, leading to a lower rate of complete clinical response.
Clinical Significance of Abnormal Serum LGALS3BP Expression in Patients with Idiopathic Inflammatory Myopathies.
J Inflamm Res
November 2024
Department of Clinical Laboratory, the First Affiliated Hospital of Guangxi Medical University, Key Laboratory of Clinical Laboratory Medicine of Guangxi Department of Education, Nanning, Guangxi, 530021, People's Republic of China.
Article Synopsis
- - The study investigates the role of LGALS3BP as a potential biomarker to differentiate between four subtypes of idiopathic inflammatory myopathies (IIM): dermatomyositis (DM), anti-synthetase syndrome (ASS), immune-mediated necrotizing myopathy (IMNM), and sporadic inclusion body myositis (sIBM), alongside healthy controls (HCs).
- - Using bioinformatics and enzyme-linked immunosorbent assay (ELISA), the researchers found that serum LGALS3BP levels varied significantly across the IIM subtypes and were linked to clinical features and inflammatory markers, particularly indicating a higher prevalence of interstitial lung disease (ILD) in patients with elevated levels.
- - The
Correction: Longitudinal assessment of reactivity and affinity profile of anti-Jo1 autoantibodies to distinct HisRS domains and a splice variant in a cohort of patients with myositis and anti-synthetase syndrome.
Arthritis Res Ther
December 2024
Division of Rheumatology, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, 171 64, Solna, Stockholm, Sweden.
Rationale, objectives and design of a national prospective database for idiopathic inflammatory myopathies: the Australian Myositis Registry.
Intern Med J
November 2024
Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Perth, Western Australia, Australia.
Article Synopsis
- IIMs are autoimmune diseases that lead to muscle inflammation and have serious health impacts, but due to their rarity and variability, understanding these conditions has been difficult.
- The Australian Myositis Registry (AMR) is a new national database that collects clinical and patient data from IIM patients in Australia to enhance research and improve outcomes.
- Launched in 2023 with 170 participants so far, the AMR aims to expand its reach and is significant as Australia’s first national registry for IIMs, providing crucial data for understanding the diseases' epidemiology and improving patient care.
A distinct immune landscape in anti-synthetase syndrome profiled by a single-cell genomic study.
Front Immunol
November 2024
Department of Rheumatology and Immunology, Tianjin Medical University General Hospital, Tianjin, China.
Objectives: The objective of this study was to profile the transcriptional profiles of peripheral blood mononuclear cells (PBMCs) and their immune repertoires affected by anti-synthetase syndrome (ASS) at the single-cell level.
Methods: We performed single-cell RNA sequencing (scRNA-seq) analysis of PBMCs and bulk RNA sequencing for patients with ASS (N=3) and patients with anti-melanoma differentiation-associated gene 5-positive dermatomyositis (MDA5 DM, N=3) along with healthy controls (HCs, N=4). As ASS and MDA5 DM have similar organ involvements, MDA5 DM was used as a disease control.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!